The InnoHK Centre for Immunology & Infection Limited (InnoHK C2i) and NovoBay Biotechnology Company Limited have signed a Memorandum of Understanding (MoU) to establish a strategic collaboration focused on research and development evaluation, evidence generation, rapid molecular testing, genomic surveillance and translational research. The collaboration aims to create a structured framework for evaluating advanced molecular diagnostic and sequencing technologies in oncology